LYCOS RETRIEVER 
Pfizer
built 655 days ago
Pharmaceutical concern Pfizer (NYSE:PFE) was featured in a bullish light over the weekend as an analyst appearing on Louis Rukeyser's Wall Street said 2003 should be a strong year for the stock. The analyst ... noted that PFE should stand to benefit from a GOP-dominated Congress. PFE has advanced off its late-September low and has put in several consecutive closes above its 10- week and 20-week moving averages. These intermediate-term trendlines are on the verge of a bullish crossover, the first such cross since last November. Despite this technical potential, bearish speculators continue to favor shorted PFE positions, as there are over 104 million PFE shares currently sold short. This amount to a short-interest ratio of nearly six times the equity's average daily volume.
Source:
Pfizer is the world's largest pharmaceutical firm, with annual sales near $50 billion. After the sale of its consumer health-care division to J&J, prescription drugs now account for more than 90% of sales. Top sellers include cholesterol-lowering Lipitor, Celebrex for arthritis, Viagra for impotence, and Lyrica for epilepsy and some types of neuropathic pain. Recently approved drugs with blockbuster potential include oncology drug Sutent and Chantix for smoking cessation.
Source:
This is not the first time Pfizer has delayed notification. Pfizer waited 6 weeks before notifying employees about the previous data breach, and 5 weeks have passed before public acknowledgement of this second data breach. Blumenthal has criticized Pfizer on both data breach accounts, and has requested information about their data security and data breach notification policies.
Source:
Even before Pfizer's generous buyout offer, Vicuron, based in King of Prussia, Pa., had a market capitalization just shy of $1 billion. Not bad for an unprofitable company with no products on the market. It was the two drugs that Vicuron has in development, anidulafungin and dalbavancin, that attracted the attention of investors — and ultimately Pfizer. Both are currently under review for approval by the Food and Drug Administration.
Source:
Pfizer Inc. and the Pfizer Foundation are ... funding the Academic Alliance for AIDS Care and Prevention in Africa, a collaboration of Ugandan and North American infectious disease experts. In partnership with Makerere University Medical School, the Alliance, Pfizer Inc. and the Pfizer Foundation will help build, equip, and operate a new AIDS prevention, treatment, and training center in Kampala, Uganda. The center will not only treat patients, but also serve as a regional training center for African health care practitioners.
Source:
Pfizer attorney Malcolm Wheeler calls FDA chief counsel Daniel E. Troy requesting that the agency intervene in a lawsuit filed against the company. The lawsuit alleges that Zoloft, an antidepressant drug manufactured by Pfizer, caused Victor Motus of California to kill himself on November 12, 1998. It ... says that the drug company should have warned physicians that Zoloft might cause suicidal thoughts in some people. On September 3, the FDA files a brief stating that the agency’s scientists have found no evidence that antidepressants cause suicidal thoughts. Furthermore, the FDA argues, if Pfizer had warned doctors of such a link, it would have been a violation of the law because all warnings must first be vetted by the FDA. According to Troy, the agency has “absolute control over the label.” This position, notes one of the plaintiff attorneys in the Pfizer case, contradicts arguments that Troy made when he was practicing in the private sector.
Source:
MORE ABOUT
Pfizer